Novovax: Long-term value in vaccines

by John McCamant, editor The Medical Technology Stock Letter

New management team members at Novovax (NVAX) have the experiences and skill sets necessary to drive the company's vaccines to commercialization.

We expect this to result in substantial creation of shareholder value for investors in this biotechnology stock.